2nd deadliest cancer
Colorectal cancer is the second deadliest cancer worldwide for both sexes, with over 900,000 annual deaths and 1.9 million annual new cases.2
Overview
Early detection of CRC is crucial
Colorectal cancer is the 2nd deadliest cancer worldwide leading to almost 1 million deaths per year.2 Despite evidence that screening can reduce mortality, population screening is not applied globally evenly and where applied, compliance may appear suboptimal. 1 in 10 colon cancers and 1 in 4 rectal cancers will be diagnosed in adults <50 years old.3 About 5–10% of colon and rectal cancer cases diagnosed are attributed to genetic risks.4
Early detection
With a 5-year survival rate of 90% in early stages, detecting colorectal cancer early may represent a crucial aspect.5
Screening compliance
Participation in CRC screening programs varies greatly between European countries. An analysis showed that the majority of countries achieved participation rates over 45%, with Croatia and the Czech Republic having the lowest participation rates (< 25%), followed by France (34.3%).6
navify® Algorithms, LGI-Flag
LGI-Flag is a software system that performs algorithm‐based analysis of demographic information and lab test results and provides personal scores to indicate individuals with higher probability of harboring colorectal cancer (CRC) compared to the general population.¹
9 in 10 adults diagnosed at an early stage will still be alive after 5 years.7
Fewer than one-third (~33%) of colorectal cancers are diagnosed at an early stage7— partially reflecting suboptimal screening participation.
~33%early stage diagnosis.7
LGI-Flag, a validated model for identification of individuals with higher CRC probability compared with general population1
The medical algorithm LGI-Flag uses the results of a conventional complete blood count (CBC) together with demographic information (age, sex)1 to uncover interrelationships between CBC results and subtle changes in their trends of time.
Algorithm parameters
LGI-Flag is a software system that performs algorithm‐based analysis of demographic information and lab test results and provides personal scores to indicate individuals with higher probability of harboring colorectal cancer (CRC) compared to the general population.1
Clinical use
Supports healthcare professionals in decision-making and is not intended as a screening or standalone diagnostic tool. It is not intended to rule-out or to be used to waive screening or further diagnosis.1
Indicated target audience
Intended to be used by healthcare organizations and healthcare professionals to aid in identifying individuals, age 40 and above, of the general population who are at increased risk of harboring CRC compared to the general population for whom further evaluation is recommended.1
Benefits
Enhance colorectal screening: the key advantages of LGI-Flag
By leveraging LGI-Flag, healthcare providers can enhance patient screening processes, improve detection rates and ultimately drive better health outcomes in the fight against colorectal cancer.1,8
8×more effective
More CRC cases (all stages) detected in the flagged population compared with routine CRC colonoscopy screenings8
76 %operational impact
proportion of overdue patients agreed to undergo screening (following personalized outreach)8
70%lower GI findings
in the flagged patients who completed colonoscopy (or screening)8
Integration via navify Algorithm Suite
Experience a single integrated platform designed for healthcare providers and laboratories that simplifies IT complexity while reducing the risk of vulnerabilities. With integrated Roche and partner medical algorithms, we provide a comprehensive solution that streamlines processes and enhances collaboration.
Single point of contact for customer support
Roche offers centralized customer support for all algorithms in our portfolio to ensure consistency and reliability. We manage issues that arise for all hosted algorithms, streamlining the process and eliminating the need for customers to engage with individual providers.
Security and data privacy
Security and data privacy are central to Roche's operations, founded on a "Security and Privacy by Design" philosophy and ISO/IEC 27001 certification. Our dedicated technical team performs ongoing risk assessments, penetration tests, and network monitoring to minimize IT complexity and vulnerabilities, prioritizing data confidentiality to protect patient information across all partners.
Frequently asked questions
If you don’t find answers to your questions here, we’re happy to provide more information and discuss your needs in detail.
Roche Diagnostics
At Roche Diagnostics, we understand the need to go beyond our products and see the bigger picture, creating a world where product and services come together. Roche Service Solutions refers to our service offering and encompasses our full service portfolio. Our total solution package means we can provide you with the personalised mix of products and services you need. Our digital services enable you to quickly connect with us and help make your life more manageable.
- LGI-Flag V1.0 User Guide V1.0. Material number 10650222001.
- Ferlay J, et al. Global Cancer Observatory: Colorectum [Internet; published 2024; cited 2025 July 10]. Available from: https://gco.iarc.who.int/media/globocan/factsheets/cancers/41-colorectum-fact-sheet.pdf.
- REACCT Collaborative, et al. Characteristics of early-onset vs late-onset colorectal cancer: a review. JAMA Surg. 2021 Sep;156(9):865-8745. DOI:10.1001/jamasurg.2021.2380.
- Not every digital product is available in all markets. The use of any third-party app is subject to a separate license agreement with the respective third-party app developer. Roche gives no warranties (express or implied) with regard to any third-party app. Third-party apps might not be available in your country. This website and its content may be accessible worldwide, Roche assumes no liability with regard to the access to the information, which may not be compatible with legislations or regulations in force in your country.
- MC--11187